
PMC:7536954 / 157-1303
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 66-70 | Body_part | denotes | skin | http://purl.org/sig/ont/fma/fma7163 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 66-70 | Body_part | denotes | skin | http://purl.obolibrary.org/obo/UBERON_0000014 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T6 | 0-24 | Disease | denotes | Hidradenitis suppurativa | http://purl.obolibrary.org/obo/MONDO_0006559 |
T7 | 26-28 | Disease | denotes | HS | http://purl.obolibrary.org/obo/MONDO_0006559 |
T8 | 53-78 | Disease | denotes | inflammatory skin disease | http://purl.obolibrary.org/obo/MONDO_0006501 |
T9 | 66-78 | Disease | denotes | skin disease | http://purl.obolibrary.org/obo/MONDO_0005093 |
T10 | 260-265 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
T11 | 369-397 | Disease | denotes | systemic lupus erythematosus | http://purl.obolibrary.org/obo/MONDO_0007915 |
T12 | 378-397 | Disease | denotes | lupus erythematosus | http://purl.obolibrary.org/obo/MONDO_0004670 |
T13 | 399-402 | Disease | denotes | SLE | http://purl.obolibrary.org/obo/MONDO_0007915 |
T14 | 488-506 | Disease | denotes | drug‐induced lupus | http://purl.obolibrary.org/obo/MONDO_0016474 |
T15 | 501-506 | Disease | denotes | lupus | http://purl.obolibrary.org/obo/MONDO_0004670 |
T16 | 543-545 | Disease | denotes | HS | http://purl.obolibrary.org/obo/MONDO_0006559 |
T17 | 551-554 | Disease | denotes | SLE | http://purl.obolibrary.org/obo/MONDO_0007915 |
T18 | 662-670 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T19 | 708-710 | Disease | denotes | HS | http://purl.obolibrary.org/obo/MONDO_0006559 |
T20 | 715-718 | Disease | denotes | SLE | http://purl.obolibrary.org/obo/MONDO_0007915 |
T21 | 733-741 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T22 | 742-751 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T23 | 838-846 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T24 | 847-856 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T25 | 973-981 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 33-34 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T2 | 66-70 | http://purl.obolibrary.org/obo/UBERON_0000014 | denotes | skin |
T3 | 66-70 | http://purl.obolibrary.org/obo/UBERON_0001003 | denotes | skin |
T4 | 66-70 | http://purl.obolibrary.org/obo/UBERON_0002097 | denotes | skin |
T5 | 66-70 | http://purl.obolibrary.org/obo/UBERON_0002199 | denotes | skin |
T6 | 66-70 | http://www.ebi.ac.uk/efo/EFO_0000962 | denotes | skin |
T7 | 260-287 | http://purl.obolibrary.org/obo/PR_000000134 | denotes | tumor necrosis factor‐alpha |
T8 | 289-292 | http://purl.obolibrary.org/obo/PR_000000134 | denotes | TNF |
T9 | 419-420 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T10 | 452-455 | http://purl.obolibrary.org/obo/PR_000000134 | denotes | TNF |
T11 | 575-580 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T12 | 778-783 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 26-28 | Chemical | denotes | HS | http://purl.obolibrary.org/obo/CHEBI_74056 |
T2 | 151-162 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T3 | 164-173 | Chemical | denotes | retinoids | http://purl.obolibrary.org/obo/CHEBI_26537 |
T4 | 282-287 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
T5 | 458-468 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T6 | 488-492 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T7 | 543-545 | Chemical | denotes | HS | http://purl.obolibrary.org/obo/CHEBI_74056 |
T8 | 575-580 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T9 | 708-710 | Chemical | denotes | HS | http://purl.obolibrary.org/obo/CHEBI_74056 |
T10 | 778-783 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T11 | 812-830 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T12 | 905-917 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T13 | 936-954 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
29 | 260-287 | Gene | denotes | tumor necrosis factor‐alpha | Gene:7124 |
30 | 288-295 | Gene | denotes | (TNF)‐α | Gene:7124 |
31 | 452-457 | Gene | denotes | TNF‐α | Gene:7124 |
32 | 695-702 | Species | denotes | patient | Tax:9606 |
33 | 164-173 | Chemical | denotes | retinoids | MESH:D012176 |
34 | 224-234 | Chemical | denotes | adalimumab | MESH:D000068879 |
35 | 812-830 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
36 | 905-917 | Chemical | denotes | azithromycin | MESH:D017963 |
37 | 936-954 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
38 | 0-24 | Disease | denotes | Hidradenitis suppurativa | MESH:D017497 |
39 | 66-78 | Disease | denotes | skin disease | MESH:D012871 |
40 | 369-397 | Disease | denotes | systemic lupus erythematosus | MESH:D008180 |
41 | 399-402 | Disease | denotes | SLE | MESH:D008180 |
42 | 551-554 | Disease | denotes | SLE | MESH:D008180 |
43 | 662-670 | Disease | denotes | COVID‐19 | MESH:C000657245 |
44 | 715-718 | Disease | denotes | SLE | MESH:D008180 |
45 | 733-741 | Disease | denotes | COVID‐19 | MESH:C000657245 |
46 | 742-751 | Disease | denotes | infection | MESH:D007239 |
47 | 838-846 | Disease | denotes | COVID‐19 | MESH:C000657245 |
48 | 847-856 | Disease | denotes | infection | MESH:D007239 |
49 | 973-981 | Disease | denotes | COVID‐19 | MESH:C000657245 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T3 | 0-24 | Phenotype | denotes | Hidradenitis suppurativa | http://purl.obolibrary.org/obo/HP_0040154 |
T4 | 26-28 | Phenotype | denotes | HS | http://purl.obolibrary.org/obo/HP_0040154 |
T5 | 53-78 | Phenotype | denotes | inflammatory skin disease | http://purl.obolibrary.org/obo/HP_0011123 |
T6 | 260-265 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
T7 | 333-354 | Phenotype | denotes | autoimmune conditions | http://purl.obolibrary.org/obo/HP_0002960 |
T8 | 369-397 | Phenotype | denotes | systemic lupus erythematosus | http://purl.obolibrary.org/obo/HP_0002725 |
T9 | 399-402 | Phenotype | denotes | SLE | http://purl.obolibrary.org/obo/HP_0002725 |
T10 | 543-545 | Phenotype | denotes | HS | http://purl.obolibrary.org/obo/HP_0040154 |
T11 | 551-554 | Phenotype | denotes | SLE | http://purl.obolibrary.org/obo/HP_0002725 |
T12 | 708-710 | Phenotype | denotes | HS | http://purl.obolibrary.org/obo/HP_0040154 |
T13 | 715-718 | Phenotype | denotes | SLE | http://purl.obolibrary.org/obo/HP_0002725 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 266-274 | http://purl.obolibrary.org/obo/GO_0070265 | denotes | necrosis |
T2 | 266-274 | http://purl.obolibrary.org/obo/GO_0019835 | denotes | necrosis |
T3 | 266-274 | http://purl.obolibrary.org/obo/GO_0008219 | denotes | necrosis |
T4 | 266-274 | http://purl.obolibrary.org/obo/GO_0001906 | denotes | necrosis |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 0-302 | Sentence | denotes | Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent. |
T5 | 303-507 | Sentence | denotes | Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use of TNF‐α inhibitors due to the risk of drug‐induced lupus. |
T6 | 508-680 | Sentence | denotes | 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic. |
T7 | 681-831 | Sentence | denotes | We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐label secukinumab associated with hydroxychloroquine. |
T8 | 832-967 | Sentence | denotes | Since COVID‐19 infection was diagnosed, secukinumab was interrupted, and azithromycin was combined with hydroxychloroquine for 2 weeks. |
T9 | 968-1146 | Sentence | denotes | When COVID‐19‐related symptoms completely resolved, nasopharyngeal swab results were negative and secukinumab therapy was reintroduced after 8 weeks from the last administration. |